What's Happening?
Lantern Pharma has announced a successful outcome from the FDA regarding its Type C meeting request for the HARMONIC Phase 2 trial of LP-300 in never-smokers with non-small cell lung cancer (NSCLC). The FDA raised no objections to key protocol amendments,
including enriching enrollment for patients with EGFR exon 21 L858R mutations, extending LP-300 dosing to a maximum of eight cycles, and transitioning to a single-arm study design. These changes align with emerging data and support a clearer regulatory and partnering path.
Why It's Important?
The FDA's approval of the protocol amendments is a significant milestone for Lantern Pharma, as it provides a more focused regulatory path for the HARMONIC trial. This development could enhance the company's ability to address the unmet needs of the never-smoker NSCLC patient population, particularly those with EGFR exon 21 L858R mutations. The trial's success could lead to new treatment options for this distinct group, potentially improving patient outcomes and expanding Lantern Pharma's market presence.
What's Next?
Lantern Pharma plans to focus future HARMONIC enrollment on patients with the EGFR exon 21 L858R mutation. The company aims to generate a more focused data set to support discussions with regulators and potential partners. The trial is currently enrolling patients in the United States and Taiwan, with additional data updates expected in the second half of 2026. Lantern Pharma is also exploring collaboration opportunities to maximize the commercial potential of LP-300.
